Vaccines to 2014 - Freedonia Market Research

Vaccines to 2014

Vaccines to 2014 - Freedonia Market Research
Vaccines to 2014
Published Aug 01, 2010
294 pages — Published Aug 01, 2010
Price US$ 4,700.00  |  Buy this Report Now

About This Report

  
Abstract:

US demand for vaccines will advance 5.6 percent annually through 2014, driven by the development of new vaccines to treat complex human diseases, such as cancer. Public health recommendations for adult and adolescent immunization will produce continued strong sales in this segment, which has reached the level of pediatric vaccines sales.This study analyzes the $10.8 billion US vaccines industry. It presents historical demand data for the years 1999, 2004 and 2009, and forecasts for 2014 and 2019 by vaccine type (e.g., pediatric, adult and adolescent, pandemic influenza, biodefense, developmental, travel, livestock, companion animal, poultry).The study also considers market environment factors, details industry structure, evaluates company market share and profiles 18 industry competitors, including Sanofi-Aventis, Merck and GlaxoSmithKline.

  
Source:
Document ID
2667
Country
Format:
PDF Adobe Acrobat
Buy Now

Freedonia Market Research—Reports provide industry insights targeting market size, product and market segmentation, product and market forecasts, industry composition, market leaders and business trends.

About the Author


Cite this Report

  
MLA:
Freedonia Market Research. "Vaccines to 2014" Aug 01, 2010. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/Freedonia-Market-Research/Vaccines-to-2014-2039-360>
  
APA:
Freedonia Market Research. (2010). Vaccines to 2014 Aug 01, 2010. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/Freedonia-Market-Research/Vaccines-to-2014-2039-360>
  
US$ 4,700.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.